Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

Claims 1-52. (Canceled)

Claim 53. (Currently Amended) A method for inducing a cellular immune response in a human subject directed to a **Prostate Stem Cell Antigen** (PSCA) protein of ~~**Fig. 1B**~~ SEQ ID NO:2, the subject having a cancer overexpressing **the** ~~**Prostate Stem Cell Antigen**~~ (PSCA) protein **of SEQ ID NO:2**, said cancer selected from the group consisting of prostate cancer, prostate cancer metastasized to bone, bladder cancer, and pancreatic cancer, the method comprising administering to the subject **dendritic cells pulsed with the** PSCA protein of ~~**Fig. 1B**~~ (SEQ ID NO:2) or pulsed with an immunogenic fragment **of the PSCA protein of SEQ ID NO:2** ~~**thereof.**~~

Claims 54-57. (Canceled)

Claim 58. (Previously presented) The method of claim 53, wherein the PSCA protein fragment consists of amino acid residues 2 through 50 as described in SEQ ID NO:2.

Claim 59. (Previously presented) The method of claim 53, wherein the PSCA protein fragment consists of amino acid residues 85 through 123 as described in SEQ ID NO:2.

Claim 60. (Previously presented) The method of claim 53, wherein the PSCA protein fragment consists of amino acid residues 46 through 109 as described in SEQ ID NO:2.

Claim 61. (Previously presented) The method of claim 53, wherein the PSCA protein fragment consists of amino acid residues 18 through 98 as described in SEQ ID NO:2.

Claim 62. (Previously presented) The method of claim 53, wherein the PSCA protein fragment consists of amino acid residues 22 through 99 as described in SEQ ID NO:2.

Claim 63. (Previously presented) The method of claim 53, wherein the PSCA protein fragment consists of amino acid residues 21 through 50 as described in SEQ ID NO:2.

Claim 64. (Previously presented) The method of claim 53, wherein the PSCA protein fragment consists of amino acid residues 46 through 85 as described in SEQ ID NO:2.

Claims 65-69. (Canceled)

Claim 70. (Previously presented) The method of claim 53, wherein the PSCA protein fragment consists of amino acid residues 18 through 50 as described in SEQ ID NO:2.

Claim 71. (Previously presented) The method of claim 53, wherein the PSCA protein fragment consists of amino acid residues 46 through 98 as described in SEQ ID NO:2.

Claim 72. (Canceled)

Claim 73. (Canceled)

Claim 74. (Previously presented) The method of claim 53, wherein the protein fragment consists of amino acid residues 1 through 123 as described in SEQ ID NO:2.

Claims 75-77. (Canceled)

Claim 78. (Currently amended) A method for inducing an immune response in a mammalian subject directed to a PSCA protein **of ~~Fig. 1B~~** SEQ ID NO:2, the subject having a cancer overexpressing a Prostate Stem Cell Antigen (PSCA) protein **of SEQ ID NO:2**, said cancer selected from the group consisting of prostate cancer, prostate cancer metastasized to bone, bladder cancer, and pancreatic cancer, the method comprising administering to the subject a PSCA protein of **~~Fig. 1B~~** (SEQ ID NO:2) or an immunogenic fragment thereof, wherein dendritic cells are used to present PSCA the protein or protein fragments to T cells in the context of MHC class I and II molecules.

Claim 79. (Previously presented) The method of claim 78 wherein the immune response is a humoral response, whereby an antibody is produced.

Claim 80. (Previously presented) The method of claim 78, wherein the subject is a human.

Claim 81. (Previously presented) The method of claim 78, wherein the subject is a sheep, rat, dog, cat, pig, horse, or mouse.

Claim 82. (Previously presented) The method of claim 78, wherein the PSCA protein fragment consists of amino acid residues 2 through 50 as described in SEQ ID NO:2.

Claim 83. (Previously presented) The method of claim 78, wherein the PSCA protein fragment consists of amino acid residues 85 through 123 as described in SEQ ID NO:2.

Claim 84. (Previously presented) The method of claim 78, wherein the PSCA protein fragment consists of amino acid residues 46 through 109 as described in SEQ ID NO:2.

Claim 85. (Previously presented) The method of claim 78, wherein the PSCA protein fragment consists of amino acid residues 18 through 98 as described in SEQ ID NO:2.

Claim 86. (Previously presented) The method of claim 78, wherein the PSCA protein fragment consists of amino acid residues 22 through 99 as described in SEQ ID NO:2.

Claim 87. (Previously presented) The method of claim 78, wherein the PSCA protein fragment consists of amino acid residues 21 through 50 as described in SEQ ID NO:2.

Claim 88. (Previously presented) The method of claim 78, wherein the PSCA protein fragment consists of amino acid residues 46 through 85 as described in SEQ ID NO:2.

Claims 89 -92. (Canceled)

Claim 93. (Previously presented) The method of claim 78, wherein the PSCA protein fragment consists of amino acid residues 85 through 99 as described in SEQ ID NO:2.

Claim 94. (Previously presented) The method of claim 78, wherein the PSCA protein fragment consists of amino acid residues 18 through 50 as described in SEQ ID NO:2.

Claim 95. (Previously presented) The method of claim 78, wherein the PSCA protein fragment consists of amino acid residues 46 through 98 as described in SEQ ID NO:2.

Claim 96. (Previously presented) The method of claim 78, wherein the PSCA protein fragment consists of amino acid residues 85 through 99 as described in SEQ ID NO:2.

Claim 97. (Previously presented) The method of claim 78, wherein the protein fragment consists of amino acid residues 1 through 123 as described in SEQ ID NO:2.

Claim 98. (Canceled)

Claim 99. (Previously presented) The method of claim 53, wherein the cancer is prostate cancer, prostate cancer metastasized to bone.

Claim 100. (Previously presented) The method of claim 78, wherein the immune response is a humoral immune response.